Please enter verification code
Confirm
The Possible Protective Role of Both, Rosiglitazone and Repaglinide on Liver and Kidney of Diabetic Guinea Pig (Caviaporcellus)
International Journal of Ecotoxicology and Ecobiology
Volume 1, Issue 2, September 2016, Pages: 39-48
Received: Jun. 4, 2016; Accepted: Jun. 20, 2016; Published: Jul. 28, 2016
Views 3951      Downloads 118
Authors
Ali Abd Alsalaam, Department of Pharmacology, Faculty of Medicine, Al-Azhar University, Assiut, Egyspt
Fathy M. Elshaer, Department of Zoology, Faculty of Science, Al-Azhar University, Cairo, Egypt
Hamdi Abdou Mansour, Department of Pharmacology, Faculty of Medicine, Al-Azhar University, Assiut, Egyspt
Article Tools
Follow on us
Abstract
Diabetes mellitus is one of the most costly and burdensome chronic disease of our time. Diabetes mellitus is a metabolic disorder characterized by hyperglycemia due to resistance to the action of insulin, insufficient insulin secretion, or both. Diabetes mellitus causes nephropathy and fatty change in the liver and vascular changes. Rosiglitazone and repaglinide are new anti-diabetic agents. Rosiglitazone is a thiazolidinedione's agent acting as insulin-sensitizer. Repaglinide a non-sulphonyl urea insulin secretagogue, is a prandial glucose regulator. The present study is aimed to assess the potential protective role of Rosiglitazone and Repaglinide on Liver and Kidney tissues of diabetic guinea pig (Caviaporcellus). The used Guinea pigs were divided into five groups. Diabetes mellitus is induced in 4 groups of them by oral administration of fructose 50% concentration. One of the diabetic groups was served as diabetic non treated and the other 3 groups were treated by Rosiglitazone, Repaglinide and a combination of both drugs, respectively. Blood samples were collected for the biochemical studies. The animals were sacrificed and the liver and kidney were excised to be used for the histopathological studies. The present study showed that, the combination of rosiglitazone & repaglinide may have a synergistic protective effect against diabetes mellitus - induced renal and liver tissues damage. This study proved that the combination of rosiglitazone &repaglinide in treatment of diabetes mellitus is better than rosiglitazone or repaglinidealone in protection of the Liver and Kidney tissues of diabetic Guinea pigs, Caviaporcellus.
Keywords
Rosiglitazone, Repaglinide, Liver, Kidney, Guinea Pig, (Caviaporcellus)
To cite this article
Ali Abd Alsalaam, Fathy M. Elshaer, Hamdi Abdou Mansour, The Possible Protective Role of Both, Rosiglitazone and Repaglinide on Liver and Kidney of Diabetic Guinea Pig (Caviaporcellus), International Journal of Ecotoxicology and Ecobiology. Vol. 1, No. 2, 2016, pp. 39-48. doi: 10.11648/j.ijee.20160102.13
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Adler, A. T.; Neil, H. A.; Manley, S.; Halman, R. R. and Turner, R.C. (1999): Hyperglycemia and hyperinsulinemia at diagnosis of diabetes in the United Kingdom Prospective Diabbetes study (UKPDs 47).Am Heart J 138: 353-359.
[2]
Expert committee (1997): Diagnosis and classification of diabetes mellitus, Diabetes Care 20: 1183-1197.
[3]
De-Fronzo, R. A.; Bonadonna, R. C. and Ferannini, E. (1997): Pathogenesis of NIDDM: a balanced overview. Diabetes Care; 15: 318-368.
[4]
Stern, M.P.; Williams, K. and Haffner, S. M. (2002): Identification of persons at high risk for type -2 diabetes mellitus Ann Intern Med 136: 575-581.
[5]
Taylor, S. and Arioglu, E. (1999): Genetically defined forms of diabetes in children. JclinEndocrinolMetab 84: 4390-4396.
[6]
Harris, RZ.; Inglis, AML. and Miller, AK. (1999): Rosiglitazone has no clinically significant effect on nifedinepharmacokinetics.J.clin. Pharmacol; 39:1189-1194.
[7]
Frank, A. and Mitros, S. (1992): Alcohol Related Liver Disease and Nonalcoholic Steatohepatitis.Eur. J.clin.phamacol 59:53-56.
[8]
Actos prescribing information (2002): Takeda pharmaceuticals America, Inc; Indianapolis, IN:Eli Lilly and company.
[9]
Avandia prescribing informations (2003): Philadelphia PA: SmithKline Beecham Pharmaceuticals.
[10]
Lebovitz, H. E.; Dole, J. F.; Patwardhan, R.; Rappaport, E. B. and Freed, M. I. (2001): Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J ClinEndocrinolMetab 86: 280-288.
[11]
Fonseca, V.; Rosenstock, J. and Patwardhan, R. (2000): Effect of metformin and rosiglitazone combination therapy in patients with type -2 diabetes mellitus: a randomized controlled trial. JAMA 283: 1695-1702.
[12]
Willson, T. M.; Lambert, M. H. and Kliewer, S. A. (2001): Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem; 70:341-367.
[13]
Picard, F. and Auwerx, J. (2002): PPAR (gamma) and glucose homeostasis. Annu Rev Nutr 22: 167-197.
[14]
Gromada, J.; Dissing, S.; Kofod, H. and Frokjaer-Jensen, J. (1995): Effects of the hypoglycemic drugs repaglinide and glibenclamide on ATP-sensitive potassium channels and cytosolic calcium levels in BTC3 cells and rat pancreatic beta cells. Diabetologia; 38: 1025-1032.
[15]
Fuhlendorff, J.; Rorsman, P.; Kofod, H.; Brand, CL.; Rolin, B.; Mackay, P.; Shymco, r. and Carr, RD. (1998):Stimulation of insulin release by repaglinide and glibenclaide involves both common and distinct processes.diabetes 47:345-351.
[16]
Hansen, A. M. K.; Christensen, I. T. and Wahl, P. (2001): Repaglinide and natiglinide are differently affected by a single point mutation in SURI/KIR6.2 Channels. Diabetes; 50 Suppl. 2: A 9.
[17]
Gumieniczek, A. (2003): Effect of repaglinide Oxidative stress in kidney and liver of alloxan-induced diabetic rabbits 14: 87-93.
[18]
Owens, D. R.; Luzio, S. D.; Ismail, I. and Bayer, T. (2000): Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type-2 diabetes. Diabetes Care 23: 518-523
[19]
Culy, C. R. and Jarvis, B. (2001): Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus. Drugs 61:1625-1660.
[20]
Roberto, M.; Miatello, M.; Damiani, T. and Hector, L. (1998): Cardiovascular kinin generating capability in hypertensive fructose fed rats.J.Hypertens., 16: 1273-1277.
[21]
Mahmoud, K. A. F. (2002): Comparative study between angiotensin II receptor antagonist (Losartan) andangiotensin converting enzyme inhibitor (Ramipril) on left ventricular hypertrophy, insulin resistance and vascular reactivity in rats. Thesis, submitted for partial fulfillment of M.D.in pharmacology. Faculty of medicine Ain Shams University.
[22]
Beck–Niclsen, H.; Pederson, O. and Lindstor, H. O. (1980): Impaired cellular insulin binding and insulin sensitivity induced by hight fructose feeding in normal subjects. Am. J. Clin. Nutr 33: 273-278.
[23]
Paget, G. E. and Barnes, JM. (1964): Toxicity tests. In: Laurence DR, Bacharach AL (ed.) Evaluation of drug activities. Pharmaco metrics (p 161). London: Academic Press.
[24]
Timm, K.I. (1979): Orbital venous anatomy of the rat.Lab. Animal Science; 29:636-638.
[25]
Matthews, D.R.; Hosker, JP. and Redunski, AS. (1985): Homeostasis model assessment: insulin resistance and B cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
[26]
Steel, R. G. D. and Torrie, J. H. (1960): Principles and Procedures of Statistics. (With special Reference to the Biological Sciences.) McGraw-Hill Book Company, New York, Toronto, London, 481 S., 15 Abb.; 8s 6d
[27]
Thorup, C.; Ollerstam, A.; Persson, E. G.; Torffvit, O. (2000): Increased tubuloglomerular feedback reactivity is associated with increased NO production in the streptozotocin-diabetic rat. J. Diabetes Compl. 14, p. 46-52.
[28]
Teckman, J. H.; AN, J. K.; Loethen, S.; Perimutter, D. H. (2002): Fasting in a1-antitrypsin deficient liver: constitutive activation of autophagy. Am. J. Physiol., (263): 1156-1165,
[29]
Dunstan D, Zimmet P, Welborn T. (2002): The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25: 829-34.
[30]
Isomaa, B.; Almgren, P. and Tuomi, T. (2001): Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care24: 683-689.
[31]
Lakka, H. M.; Laaksonen, D. E. and Lakka, T. A. (2002): The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA; 288: 2709-2716.
[32]
Thornburn, A. W.; Storlein, L. H.; Jenkins, A. B.; Khouri, S. and Kraegen, E. W. (1989): Fructose –induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am.J.Clin.Nutr 49:1155-1163.
[33]
Biavatti, M. W.; Farias, S. N. and Pradio, S. R. T. (2004): Preliminary studies on Campomanesiaxanthocarpa (Berg.) and Cupheacarthagenesis (Jacq.) J. F. Macbr. A queous extract: weight control and biochemical parameters. J. Ethnopharmacol 393: 385-389.
[34]
Sanchez-Salgado, J. C.; Ortiz-Andrade, R. R.; Aguirre-Crespo, F.; Vergara-Gallcia, J.; Leon-Rivera, I.; Montes, S.; Villalobos-Molina, R. and Estrada-Soto, S. (2007): Hypoglycemic, vasorelaxant and hepatoprotective effects of Cochlospermumvitifolium (Willd.) Sprengel: A potential agent for the treatment of metabolic Syndrome J. Ethnopharmacol 109, p. 400-405.
[35]
Cavalli, V.L.; Sordil, C.; Toninil, K.; Grandol, A.; Muneronl, T.; Guigil, A.; Junior, R. and Avaliação, W. A. (2007): in vivo do efeitohipoglicemiante de extratosobtidos da raiz e folha de bardana Arctiumminus (Hill.) Bernh. Rev. Bras. Farmacogn. 17, p. 64-70,
[36]
Raskin, P. Mc Gill, J. Saad, M. F. Cappleman, J. M. Kaye, W. Khutoryansky, N. and Hale, P. M. (2004): Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone. Diabetes UK. Diabetic Medicine 21, 329–335
[37]
Diep, QN.; El Mabrouk, M. and Cohn, JS. (2002): Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation. 105: 2296–2302.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186